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Abstract
Background: Brachytherapy as adjuvant treatment for early-stage breast cancer has become widely available and
offers patients an expedited treatment schedule. Given this, many women are electing to undergo brachytherapy
in lieu of standard fractionation radiotherapy. We compare outcomes between patients treated with accelerated
partial breast irradiation (APBI) via multicatheter interstitial brachytherapy versus patients who were also eligible for
and offered APBI but who chose whole breast radiation (WBI).
Methods: Patients treated from December 2002 through May 2007 were reviewed. Selection criteria included
patients with pTis-T2N0 disease, ≤ 3 cm unifocal tumors, and negative margins who underwent breast
conservation surgery. Local control (LC), cause-specific (CSS) and overall survival (OS) were analyzed.
Results: 202 patients were identified in the APBI cohort and 94 patients in the WBI cohort. Median follow-up for
both groups exceeded 60 months. LC was 97.0% for the APBI cohort and 96.2% for the WBI cohort at 5 years (ns).
Classification by 2010 ASTRO APBI consensus statement categories did not predict worse outcomes.
Conclusion: APBI via multicatheter interstitial brachytherapy provides similar local failure rates compared to WBI at
5 years for properly selected patients. Excellent results were seen despite the high fraction of younger patients (<
60 years old) and patients with DCIS.
Introduction
Prospective randomized controlled trials have estab-
lished breast conservation therapy (BCT), consisting of
partial mastectomy and adjuvant radiation therapy,
offers equivalent disease control in women with Stage I
and II breast cancer as compared to mastectomy and
significantly superior disease control when compared to
partial mastectomy alone [1,2]. In the setting of ductal
carcinoma in situ, adjuvant radiation therapy has been
shown to increase local control [3-5].
The standard method for administering breast irradia-
tion as a part of BCT is whole breast irradiation (WBI)
delivered in five daily fractions per week for several weeks.
In an effort to expedite radiation therapy, accelerated
partial breast irradiation (APBI) techniques have been
developed. Early studies of APBI have described impress-
ively low ipsilateral breast tumor recurrence (IBTR) rates
[6,7]. We have offered APBI or WBI therapy as treatment
options for early-stage breast cancer in appropriately
selected patients since December 2002. The purpose of
this report is to review the outcomes of our multicatheter
APBI in comparison to a cohort of patients eligible for
and offered APBI but treated with WBI during the same
time interval.
Methods
Patient selection and data analysis
Patients diagnosed with Tis-T2 N0 M0 (AJCC 6
th Edition)
unifocal breast cancers ≤ 3c mi ns i z ef r o mD e c e m b e r
2002 through May 2007 who underwent breast conser-
ving therapy with negative margins and received adjuvant
radiation therapy with either APBI using multicatheter
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irradiation were identified. Patients who received neoad-
juvant systemic therapy were not eligible for APBI and
are not included in this review. All patients included in
the study were eligible for and offered the option of APBI
or WBI at initial radiation oncology consultation.
Patients who were not eligible for APBI and/or only
offered WBI were excluded from this study to limit bias.
Three patients with synchronous primaries in bilateral
breasts were identified in the APBI cohort with each
breast cancer considered independently.
APBI was generally not recommended to patients
younger than 40 years. However three patients in the
APBI cohort were in their thirties at diagnosis. Two of
these patients had prior radiation and APBI was offered to
minimize the volume of reirradiation. The third patient
declined WBI but was willing to do APBI. Given the pre-
sence of these three patients in the APBI cohort, we
included patients seen in the study time period who were
in their thirties, who received WBI, and who would have
met the other eligibility criteria for APBI.
Breast cancer subtype for invasive cancers was approxi-
mated using estrogen receptor (ER), progesterone receptor
(PR), and Human Epidermal growth factor Receptor 2
(HER2/neu) status [8].
Patients were classified according to the ASTRO con-
sensus statement for APBI [9]. Presence or absence of
lymphovascular space invasion (LVSI) was reported; how-
ever, extent was not specifically addressed. Similarly,
extensive intraductal component (EIC) was reported as
present without regards to size in the majority of reports.
Therefore the presence of LVSI or EIC was considered
cautionary. No patient was known to be BRCA1/2
positive.
Time to event and length of follow-up was calculated
using the date of final surgery as day 0. An IBTR was a
failure for local control (LC). LC was defined as one minus
the local recurrence rate (LR). Further, IBTR were classi-
fied as “true recurrence” when they occurred in the same
quadrant as the initial tumor, or “elsewhere” if they
occurred in a separate quadrant. Recurrences in the supra-
clavicular, infraclavicular, internal mammary, intrapec-
toral, and axillary nodes were defined as a locoregional
recurrence (LRR).
Continuous variables were compared using two-tailed t-
tests and categorical variables were compared using Fish-
er’s exact test with p values ≤ 0.05 considered significant.
Estimates of LR, LRR, disease-free survival (DFS), cause
specific survival (CSS), and overall survival (OS) were per-
formed using the Kaplan-Meier method using SAS version
9.2 (SAS Institute Inc., Cary, NC). Survival was compared
using log-rank tests. Predictive effects were analyzed using
a Cox proportional hazards multivariate regression model
with two-sided tests. Washington University School of
Medicine Human Research Protection Office approved
this study.
Surgery
All patients underwent partial mastectomy as a part of
BCT. Negative surgical margins were defined as ≥ 2m m
of tumor free tissue on all margins or removal of the
breast tissue to the pectoralis fascia with no evidence of
tumor invasion into the fascia. Re-excisions were often
performed if the initial tumor-free margin was < 2 mm.
A small number of patients who did not have either a
sentinel lymph node biopsy or an axillary dissection
were included if they had no evidence for axillary invol-
vement at the time of diagnosis or treatment, this
included three patients undergoing APBI for an IBTR
previously treated with WBI. Axillary assessment was
not required in patients with DCIS.
Systemic therapy
Systemic therapy consisted of some combination of
endocrine, cytotoxic chemotherapy, biologic therapy, or
no systemic therapy. For patients that received APBI
and cytotoxic chemotherapy, APBI occurred prior to
cytotoxic chemotherapy in all but two cases. For
patients who received WBI and cytotoxic chemotherapy,
WBI occurred after cytotoxic chemotherapy.
Interstitial implant technique
Interstitial implants (ISI) were placed using a free hand
technique encompassing the surgical cavity with a 2 cm
margin of breast tissue in all directions. All implants were
multiplanar with an intraplane catheter spacing of 12 mm
and an interplane spacing of 1.5 to 2.0 cm. The use of
more than two planes was common. For the first 46
patients, ISI were placed intraoperatively with an open
surgical cavity. ISI insertion via real-time ultrasound gui-
dance (U/S) with a closed surgical cavity was predomi-
nantly used after this point.
The initial eight patients underwent two dimensional
brachytherapy treatment planning using pairs of orthogo-
nal plain films. All subsequent patients underwent three-
dimensional (3D) treatment planning. Within one day of
completion of ISI placement, patients underwent com-
puted tomography (CT) simulation for 3D treatment plan-
ning. CT compatible markers were placed in each
catheter. CT images were obtained using 2 mm slice thick-
ness through the ISI volume plus several centimeters of
surrounding tissue.
T h eC Td a t as e tw a st r a n s f e r r e dt ot h eb r a c h y t h e r a p y
planning system for selection of HDR dwell positions
and optimization of their relative weights. The Plato
Brachytherapy software system (Nucletron B. V., Veenen-
daal, The Netherlands) was used through November 2006
after which treatment planning was done using the
Ferraro et al. Radiation Oncology 2012, 7:53
http://www.ro-journal.com/content/7/1/53
Page 2 of 10Brachyvision system (Varian, Palo Alto, CA). The surgical
cavity was identified on the CT dataset by contouring the
seroma along with any surgical clips and density changes.
The Planning Target Volume (PTV) was created by adding
a uniform 2 cm margin to the surgical cavity contour and
subsequently limited to 5 mm away from the skin surface.
Pectoral muscle, chest wall, and axilla were excluded from
the PTV.
Dwell positions within each catheter were separated by
5-7 mm. The dosimetric goal was to cover at least 95% of
the PTV with the prescription dose while maintaining a
ratio of the prescription dose to the mean central dose of
≥ 0.70. Following the report by Arthur et al. that suggested
dose-volume predictors for fat necrosis [10], our dosi-
metric goals expanded to limit the volume receiving more
than 150% (V150) of the prescription dose to ≤ 50 mL,
V200 ≤ 20 mL, and 1-V150/V100 ≥ 0.70. Planning was
accomplished by geometric optimization of the prescrip-
tion dose to the mean central dose and subsequent user
graphical optimization.
The prescription dose was 34 Gy in ten fractions admi-
nistered twice daily with a six hour interfraction separation
over five to seven days for all but two patients. One patient
received 32 Gy in 8 fractions. The second patient was trea-
ted for a recurrent cancer in a previously irradiated field
and received a dose of 30 Gy in 10 fractions. Treatment
began one to two working days after the simulation.
Catheters were removed after the last fraction.
Quality assurance was accomplished by performing an
autoradiograph of the treatment plan and a manual expo-
sure calculation that was compared to the predicted value
based on the Paterson-Parker tables using the volume
receiving 340 cGy [11].
Whole breast irradiation
Patients in the WBI cohort were treated to the whole
breast using tangential beams. Patients received a dose of
42.56-50.4 Gy in 1.8-2.66 Gy fractions. Most patients
received a boost. 50 Gy in 200 cGy fractions to the whole
breast followed by a 10 Gy boost to the tumor bed was the
most frequent WBI dose prescription.
Results
Patient characteristics are shown in Table 1. 202
patients were identified in the APBI cohort and 94 in
the WBI cohort. Median follow-up exceeded 60 months
for both groups. One hundred one APBI patients were
≤ 60 years (50.0%), and 37 patients were ≤ 50 years old
(18.3%). Fifty-three WBI patients were ≤ 60 years old
(56.4%) and 23 patients were ≤ 50 years old (24.5%).
Characteristics are given for DCIS and invasive disease
patients in Table 2.
Seven patients treated with APBI were treated in a
previously irradiated field. Three of these patients had
Table 1 Patient demographics and tumor characteristics
All Disease
APBI WBI P value
Patients 202 94
Months Follow-up 64.3 64.1 0.422
(Range) (2.2-96.6) (4.4-98.4)
Median Age 60.0 56.9 0.087
(Range) (34.7-84.3) (33.0-83.2)
Race < 0.001*
Caucasian 169 (83.7%) 52 (55.3%)
Black 31 (15.4%) 42 (44.7%)
Other 2 (1.0%) 0 (0%)
Anatomy
Side 0.803
Right 97 (48.0%) 47 (50.0%)
Left 105 (52.0%) 47 (50.0%)
Quadrant
UOQ 88 (43.6%) 64 (68.1%) < 0.001*
UIQ 53 (26.2%) 17 (18.1%)
LIQ 29 (14.4%) 5 (5.3%)
LOQ 32 (15.8%) 8 (8.5%)
Grade 0.207
DCIS 40 (19.8%) 18 (19.1%)
I 78 (38.6%) 25 (26.6%)
II 55 (27.2%) 27 (28.7%)
III 29 (14.4%) 20 (21.3%)
Unknown 0 (0%) 4 (4.3%)
Stage
Tis 40 (19.8%) 18 (19.1%)
T1mic 3 (1.5%) 4 (4.3%)
T1a 23 (11.4%) 7 (7.4%)
T1b 67 (33.2%) 29 (30.9%)
T1c 54 (26.7%) 31 (33.0%)
T1 147 (72.8%) 71 (75.5%)
T2 15 (7.4%) 5 (5.3%)
Histology 0.092
DCIS 40 (19.8%) 18 (19.1%)
Invasive Ductal 141 (69.8%) 60 (63.8%)
Invasive Lobular 8 (4.0%) 11 (11.7%)
Invasive Tubular 7 (3.5%) 1 (1.1%)
Invasive Mucinous 5 (2.5%) 2 (2.1%)
Invasive Papillary 1 (0.5%) 2 (2.1%)
Estrogen Receptor 0.464
ER + 167 (82.7%) 71 (71.6%)
ER - 26 (12.9%) 15 (16.0%)
ER Unknown 9 (4.5%) 8 (8.5%)
Progesterone Receptor 0.489
PR + 134 (66.3%) 56 (59.6%)
PR - 59 (29.2%) 30 (31.9%)
PR Unknown 9 (4.5%) 8 (8.5%)
Her-2/Neu
(Invasive Only)
0.350
Overexpressed 14 (6.9%) 9 (4.5%)
Not Overexpressed 147 (72.8%) 62 (66.0%)
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diagnosis of breast cancer and received repeat BCT for
an IBTR diagnosed at least 10 years after the initial
diagnosis. Four patients received radiation therapy for
tumors treated earlier in life (two had Hodgkin’sl y m -
phoma and two had an upper extremity sarcoma).
Six patients treated via APBI did not have surgical
assessment of the axilla. Of these patients, 4 had pre-
viously undergone axillary dissections so reassessment
was not technically feasible. For the remaining two
patients, one had a < 1 mm focus of invasive disease in
the setting of LCIS and the other had a 6 mm focus of
invasive tubular disease.
APBI dosimetry
192 patients had ≥ 90% of the PTV covered by the pre-
scription dose and 133 patients had ≥ 95% of the PTV
covered by the prescription dose. Dose homogeneity as
assessed by 1-V150/V100 had a median value of 0.80.
Dosimetric parameter averages for the APBI patients are
given in Table 3.
Recurrence rates and survival analysis
The LR, LRR, and DFS were similar between the groups
(Table 4). Survival curves demonstrating LC for all dis-
ease, DCIS only and invasive disease only stratified by
r a d i a t i o nm e t h o da r eg i v e ni nF i g u r e1 .T h e r ew a sn o
statistical difference in OS or CSS between the groups.
While OS was not significantly lower, it was trending
lower in the APBI group compared to the WBI cohort.
A number of patients who received APBI had significant
medical co-morbidities and chose APBI over WBI.
These patients were opposed to omitting radiation ther-
apy and chose APBI for the convenience of a shorter
time commitment. Seven of these patients died from
their pre-existing comorbidities (Table 5).
Characteristics of patients who experienced disease
recurrence are described in Table 6. In all cases with an
initial diagnosis of regional or metastatic failure, no evi-
dence of local failure was present. The patient treated via
APBI who developed a regional failure at 55.0 months was
found to have a nodal recurrence in a portion of the axilla
that would likely have been covered using tangential beam
if given WBI. The other patient treated with APBI who
developed a regional recurrence was diagnosed at 17.1
months with an axillary nodal recurrence that would have
been superior to the upper tangent border if treated by
WBI. Both regional failures were in the APBI group and
were axillary failures. Both patients had negative sentinel
lymph node biopsies at initial diagnosis. It was estimated
that one of the site of one of the axillary failures would
have been treated with standard tangential fields if WBI
had been given and the other would not have been
included. All patients who developed regional or distant
disease remained free of IBTR at death or last follow up.
Classification by ASTRO consensus guidelines
Using the criteria to outlined in the 2009 ASTRO con-
sensus statement on APBI (Table 7), patients in both
the WBI and APBI cohorts were categorized into one of
three categories: acceptable, cautionary or unsuitable
(Table 8).
Overall, the APBI and WBI groups were significantly
different with respect to ASTRO consensus category
classification (p = 0.017). None of the ASTRO consen-
sus categories predicted LR, LRR or DFS either when
analyzed by treatment group or when analyzed in the
entire study population. In a multivariate model for LRR
in which radiation method was force entered, age, stage,
radiation method, biomarker pattern, and ASTRO con-
sensus category were all non-significant predictors.
Table 1 Patient demographics and tumor characteristics
(Continued)
Unknown 41 (20.3%) 23 (24.5%)
Disease Type
Luminal A 128 (63.4%) 51 (54.3%) 0.353
Luminal B 9 (4.5%) 7 (7.5%)
Her-2/Neu 5 (2.5%) 2 (2.1%)
Basal 16 (7.9%) 11 (3.7%)
DCIS 40 (19.8%) 18 (6.1%)
Unable to classify 4 (2.0%) 5 (5.3%)
LVSI (Invasive Only) 0.591
Present 10 (4.9%) 6 (8.1%)
Absent 152 (74.5%) 70 (91.9%)
LCIS 0.011*
Present 15 (7.4%) 17 (18.1%)
Absent 187 (92.6%) 77 (81.9%)
EIC (Invasive Only) 0.688
Present 4 (2.5%) 3 (3.9%)
Absent 148 (91.4%) 73 (96.1%)
Unknown 10 (6.2%) 0 (0%)
Endocrine Therapy
(Invasive Only)
0.182
Given 127 (78.4%) 50 (65.8%)
Not Given 34 (21.0%) 21 (27.6%)
Unknown 1 (0.6%) 5 (6.6%)
Endocrine Therapy
(DCIS Only)
0.756
Given 29 (72.5%) 14 (77.8%)
Not Given 11 (27.5%) 4 (22.2%)
Unknown 0 (0%) 0 (0%)
Cytotoxic Chemotherapy
(Invasive Only)
0.102
Given 35 (21.6%) 23 (30.3%)
Not Given 127 (78.4%) 49 (64.5%)
Unknown 0 (0%) 4 (5.3%)
* Statistically significant
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Multicatheter APBI represents the first form of partial
breast irradiation offered at Washington University as
an alternative to WBI for a select group of early-stage
breast cancer patients. Our experience suggests that
Table 2 Patient demographics and tumor characteristics for DCIS and invasive disease
DCIS Invasive
APBI WBI P value APBI WBI P value
Patients 40 18 162 76
Months Follow-up 69.4 72.7 0.502 62.9 62.1 0.543
(Range) (13.7-92.6) (24.6-87.6) (2.2-96.6) (4.4-98.4)
Median Age 59.2 56.5 0.752 61.4 58.1 0.079
(Range) (40.3-82.4) (41.4-84.2) (34.7-84.3) (33.0-84.7)
Race 0.018 < 0.001
Caucasian 31 (77.5%) 10 (55.6%) 138 (85.2%) 44 (57.9%)
Black 9 (22.5%) 8 (44.4%) 22 (13.6%) 32 (42.1%)
Other 0 (0%) 0 (0%) 2 (1.2%) 0 (0.0%)
Anatomy
Side 0.776 1.000
Right 17 (42.5%) 9 (50.0%) 80 (49.4%) 38 (50.0%)
Left 23 (57.5%) 9 (50.0%) 82 (50.6%) 38 (50.0%)
Quadrant 0.049 < 0.001
UOQ 18 (45.0%) 14 (77.8%) 70 (43.2%) 50 (65.8%)
UIQ 7 (17.5%) 3 (16.7%) 46 (28.4%) 14 (18.4%)
LIQ 6 (15.0%) 1 (5.6%) 23 (14.2%) 4 (5.3%)
LOQ 9 (22.5%) 0 (0%) 23 (14.2%) 8 (10.5%)
Estrogen Receptor 0.548 0.256
ER + 28 (70.0%) 12 (66.7%) 139 (85.8%) 59 (77.6%)
ER - 3 (7.5%) 0 (0%) 23 (14.2%) 15 (19.7%)
ER Unknown 9 (22.5%) 6 (33.3%) 0 (0%) 2 (2.6%)
Progesterone Receptor 0.727 0.369
PR + 21 (52.5%) 9 (50.0%) 113 (69.8%) 49 (64.5%)
PR - 10 (25.0%) 3 (16.7%) 49 (30.2%) 27 (35.5%)
PR Unknown 9 (22.5%) 6 (33.3%) 0 (0%) 2 (2.6%)
LCIS 0.084
Present 1 (2.5%) 3 (16.7%) 14 (8.6%) 14 (18.4%) 0.050
Absent 39 (97.5%) 15 (83.3%) 148 (91.4%) 62 (81.6%)
Table 3 Dosimetric parameters for multicatheter APBI
treatments
Median Minimum Maximum
V100 222 97.3 775
V150 43.6 19.1 190
V200 15.6 7.01 58.2
(1-V150/V100) 0.8 0.45 0.88
DHI 0.83 0.56 1.00
PTV Volume 154.5 57.6 552
PTV Coverage 148.5 56.2 520
% PTV Coverage 95.7% 78.5% 100%
Cavity Volume 18.4 cc 1.4 cc 114 cc
Number of Catheters 20 10 37
Table 4 5-year survival rates and number of failures
APBI WBI P value
Overall
Local Recurrence Rate 3.04% (5) 3.82% (3) 0.721
Locoregional Recurrence Rate 4.25% (7) 3.82% (3) 0.902
Disease-Free Survival 94.3% (9) 93.4% (8) 0.870
Cause Specific Survival 99.4% (1) 98.9% (1) 0.954
Overall Survival 91.9% (15) 96.7% (3) 0.113
DCIS
Local Recurrence Rate 2.56% (1) 6.25% (1) 0.573
Disease-Free Survival 97.4% (1) 93.8% (1) 0.573
Cause Specific Survival 100% (0) 100% (0) -
Overall Survival 97.5% (1) 100% (1) 0.843
Invasive Disease
Local Recurrence Rate 3.24% (4) 3.10% (2) 0.939
Locoregional Recurrence Rate 4.80% (6) 3.10% (2) 0.669
Disease-Free Survival 93.8% (8) 94.1% (4) 0.920
Cause Specific Survival 99.3% (1) 98.6% (1) 0.968
Overall Survival 90.4% (14) 95.6% (3) 0.093
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compared to WBI. Our series includes a significant
number of young patients and patients treated for pure
DCIS. Both of these subgroups had no significant dif-
ference in LRR, DFS, CSS or OS with APBI as com-
pared to WBI.
The most significant limitation of this series is length of
follow-up given the long natural history of breast cancer.
While the low number of events is encouraging, it does
limit the statistical analysis of predictors of these events.
As this patient population matures, occurrences will
inevitably increase, making more complex analyses possi-
ble. Selection bias may also limit the applicability of this
analysis as it is a retrospective study; however, we do
report a concurrent cohort of patients who were eligible
for and offered APBI but who selected WBI whose out-
comes were similar. It was practice in our clinic to offer
each patient both options when it was felt that either
option was technically feasible and appropriate for the
specific patient’s disease.
Previous APBI experiences
Multicatheter APBI has been practiced for over 20 years.
The Oschner clinic reported one of the first series of
patients treated in this fashion. A phase I/II trial of HDR
or Low Dose Rate (LDR) brachytherapy was initiated in
the early 1990s to evaluate tumor control in wide-field
partial breast irradiation. Patients with Tis-T2 disease
less than 4 cm in diameter with 0-3 positive axillary
nodes were treated. One in breast recurrence and three
nodal recurrences were reported at 75 months, all three
nodal recurrences in patients with extracapsular nodal
disease at the time of treatment [12]. Similar early studies
w e r ea l s op e r f o r m e da to t h e ri n s t i t u t i o n sa n db yt h e
Radiation Therapy Oncology Group 9517 cooperative
study [6,7,13,14]. An exhaustive list of APBI studies using
a variety of techniques is reported in Smith et al [9].
Recent reports are congruent with our findings.
McHaffee et al. report the Wisconsin experience with
HDR interstitial brachytherapy using multicatheter or
MammoSite balloon techniques. The majority of the 322
patients reported in the series underwent multicatheter
APBI and were planned using modern 3D-CT methods.
Patients received 32 Gy in 8 BID fractions or 34 Gy in 10
BID fractions. The 5-year LR was 4.8% and the 5-year
DFS was 89.6% [15]. Strnad et al. reports the results from
the German-Austrian Phase II trial investigating multi-
catheter brachytherapy in 274 patients. Inclusion criteria
for this study were stricter than our study, requiring
absence of LVSI and a maximum histologic grade of II/
III. The 5-year and 8-year actuarial survival was reported
as 97.7% and 95%, respectively for the entire cohort. DFS
A.
B.
C.
S
u
r
v
i
v
a
l
 
P
r
o
b
a
b
i
l
i
t
y
All Patients
1.00
0.80
0.60
0.40
0.20
0
APBI
WBI
p = 0.721
0 20 60 40
20
80 100
WBI
APBI
Months to Local Recurrence
189
Number at Risk
90
180
83
116
57
33
24
0
0
S
u
r
v
i
v
a
l
 
P
r
o
b
a
b
i
l
i
t
y
1.00
0.60
0.40
0.20
0
APBI
WBI
p = 0.573
DCIS
APBI
WBI
p = 0.939
0.80
S
u
r
v
i
v
a
l
 
P
r
o
b
a
b
i
l
i
t
y
1.00
0.60
0.40
0.20
0
0.80
Invasive Disease
02 0 6 0 40 80 100
WBI
APBI
Months to Local Recurrence
150
Number at Risk
72
142
68
89
43
26
19
0
0
02 0 6 0 40 80
WBI
APBI
Months to Local Recurrence
39
Number at Risk
18
38
16
27
14
7
2
Figure 1 Survival and time-to-recurrence for patients treated
with WBI or APBI. A. Survival curve demonstrating time to local
recurrence for all patients stratified by type of radiation received. B.
Time to local recurrence for patients treated for DCIS stratified by
type of radiation received. C. Time to local recurrence for patients
treated for invasive disease stratified by type of radiation received.
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reports a retrospective series of 199 patients treated via
LDR or HDR interstitial brachytherapy matched to a
cohort of patients treated with WBI. The LDR technique
delivered 50 Gy over 96 hours at 0.52 Gy/h. The HDR
technique delivered 32 Gy in 8 fractions BID or 34 Gy in
10 fractions BID. The LR rate was 5.0% for the APBI
cohort and 3.8% for the matched WBI patient cohort at
12 years (ns). DFS was 91% for the APBI cohort and 87%
for the WBI cohort (ns) [17]. Polgár et al. reports the
Hungarian experience with APBI, the longest follow-up
i nt h el i t e r a t u r ef o rt h eH D Rm u l t i c a t h e t e rt e c h n i q u e .
Inclusion criteria included size < 2 cm, negative margins,
maximum histologic grade of II/III, pN0-N1mic. Carci-
noma in situ or lobular carcinoma were excluded. The 5-
and 12-year LR was 4.4% and 9.3%, respectively. DFS was
75.3% at 12 years [18].
LR rate in 40 patients treated via APBI with pure
DCIS (45% high grade) in our series was less than 3% at
five years. While treatment of pure DCIS via APBI his-
torically has been controversial, recent reports have
demonstrated good local control, even when high-grade
DCIS patients are included. Jeruss et al. examined out-
comes of patients enrolled on the American Society of
Breast Surgeons APBI MammoSite registry trial treated
for pure DCIS. Eligibility criteria included size < 4.5 cm
as defined mammographically, clinically negative nodes,
and negative margins. One hundred ninety-four patients
were identified with 36% of the patients having high-
grade disease and 53% of the patients receiving endo-
crine therapy. Dose prescription was 34 Gy in 10 BID
fractions. The 5-year LR was 3.39% and DFS was 93.2%
[19]. In addition, McHaffee et al reports 32 patients
treated as described above for DCIS with no recurrences
at 5 years [15].
APBI consensus statement
In 2009, ASTRO APBI consensus statement task force
released guidelines for appropriate patient selection for
APBI [9]. After review of the literature, three general
categories were developed from a number of patient and
tumor characteristics with special focus selecting patients
for APBI outside of clinical trial. The GEC-ESTRO group
released a similar statement in 2010 [20].
Table 5 Characteristics of patients who expired and causes of death
Age at
Diagnosis
APBI
Class
T
stage
Histology Grade Biomarker
Pattern
Adjuvant
Treatment
Radiation
Modality
Time to Death
(months)
Cause of Death
77.5 cautionary 2 ductal II +/+/- R + E APBI 43.76 CAD*, Anoxic Brain Injury
after V Fib episode
35.6 unsuitable 2 ductal III -/-/+ R APBI 60.35 Recreational Drug Overdose
45.4 unsuitable 2 ductal II +/+/- R + C + E APBI 74.68 Breast Cancer
81.8 acceptable 1a ductal II +/+/- R APBI 2.83 Stroke/Fall
57.4 cautionary 1a ductal I +/+/- R APBI 8.25 Cirrhosis* with Hepatocellular
Cancer
51.6 cautionary 1a ductal III +/-/- R + E APBI 35.91 Colon Cancer*
66.5 cautionary 1a ductal III -/-/- R APBI 41.95 Myelodysplastic Syndrome
34.7 unsuitable 1b tubular I +/+/- R APBI 2.96 Urosepsis
79.1 acceptable 1b ductal II +/+/- R + E APBI 16.33 CAD*, MI
80.2 acceptable 1b ductal I +/+/- R APBI 32.20 COPD*
72.3 acceptable 1b ductal I +/+/- R + E APBI 33.71 High Grade Sarcoma*
70.7 cautionary 1b ductal III -/-/- R APBI 46.29 Breast Cancer
50.2 cautionary 1c ductal III -/-/- R + C APBI 5.95 Chemotherapy Toxicity
58.6 cautionary 1c ductal III -/-/- R APBI 13.50 Ovarian Cancer*
66.1 acceptable 1c ductal II +/+/- R + E APBI 56.48 Melanoma
68.8 acceptable 1c ductal II +/+/- R + E APBI 58.48 CHF/COPD*
66.8 acceptable 1c ductal I +/+/- R + E APBI 80.89 Stroke
49.1 unsuitable Is DCIS II +/+/- R APBI 13.70 Polycystic Kidney Disease*
67.1 cautionary Is DCIS III -/-/+ R APBI 74.35 Pneumonia (Restrictive Lung
Disease*)
70.93 acceptable 1b ductal I +/+/- R + E WBI 14.78 M. avium infection (Chronic
bronchiectasis*)
68.55 cautionary 1b ductal III +/+/- R WBI 22.01 Breast cancer
68.76 acceptable 1c mucinous II +/+/- R + E WBI 23.10 Parkinson’s Disease
48.83 unsuitable is DCIS II +/-/- R + E WBI 67.02 CAD*, MI
*condition present prior to diagnosis of breast cancer; abbreviations as Table 3. CAD: coronary artery disease, COPD: chronic obstructive pulmonary disease, MI:
myocardial infarction
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Page 8 of 10Recently, Shaitelman and colleagues reviewed patients
who received APBI via the MammoSite brachytherapy
technique as a part of BCT [21]. 1025 of the 1449
patients on the MammoSite Registry could be classified
using the ASTRO consensus criteria. Of these patients,
419 were classified as suitable, 430 as cautionary, and
176 as unsuitable. This classification scheme did not
predict different outcomes with regards to local or
regional disease recurrence, DFS, CSS, or OS. The only
statistically significant difference between the categories
was with regards to rate of distant metastases. This sug-
gests that the classification may predict disease that
tends to be more aggressive, regardless of local control
modality employed.
Beitsch and colleagues reviewed outcomes for patients
treated on the MammoSite registry trial that were retro-
spectively classified as unsuitable by the ASTRO guidelines
[22]. This analysis identified 176 patients as unsuitable and
found that there was no difference in local, regional, or
distant failure between the unsuitable and other classifica-
tions. In addition, only ER status was correlated with IBTR
on univariate analysis when looking at all patients in the
registry, suggesting that the ASTRO criteria lack power to
identify a cohort of patients that are more likely to recur
locally fail after APBI compared to WBI. Zauls et al. com-
pared patients treated with WBI and APBI via Mammo-
Site balloon therapy and did not find a difference in the
time to local failure at 4-years between the treatment
types for any of the three ASTRO classifications [23].
McHaffee et al. analyzed a cohort of 322 patients who
received APBI via multicatheter brachytherapy or Mam-
moSite balloon brachytherapy and retrospectively classi-
fied patients using the ASTRO guidelines. ASTRO
classification criteria including margin status, EIC, histol-
ogy and size, but not age did predict decreased IBTR and
LRR. Overall, the reported 5-year IBTR rate for patients
classified as suitable was 1.6% compared to 6.6% for
patients in the unsuitable cohort [15].
While APBI has been successfully adopted as treatment
modality by many institutions, there is limited phase III
data available guide patient selection. Two large, multi-
institutional phase III trials, NSABP B-39/RTOG 0413
and the GEC-ESTRO APBI trial are underway will likely
be the sources for the identification criteria that will dis-
criminate between patients that will or will not be
adversely affected with regards to disease control based
on treatment technique, if any exist. These studies
include patients with high-risk disease characteristics and
also allow for variation in APBI technique. While these
studies will help clarify outcomes and identify sub-popu-
lations of higher-risk patients not appropriate for APBI,
these data will likely not be available for multiple years.
In the interim this report offers additional evidence
regarding the safety and efficacy of APBI.
Table 8 Distribution of patient factors across ASTRO consensus statement parameters
Overall (%) Age at Diagnosis Tumor Size T Stage ER Status Histology DCIS EIC LVSI Nodal Assessment
APBI
Acceptable 58 (28.7) 101 147 147 167 194 162 158 152 156
Cautionary 104 (51.5) 64 15 55 35 8 40 4 10 0
Unsuitable 40 (19.8) 37 0 0 0 0 0 - - 6
WBI
Acceptable 16 (17.0) 41 71 71 71 83 76 73 70 67
Cautionary 47 (50.0) 30 5 23 23 11 18 3 6 0
Unsuitable 31 (33.0) 23 0 0 0 0 0 - - 9
Table 7 ASTRO APBI consensus statement categories and classification criteria
Criteria Suitable Cautionary Unsuitable
Age ≥ 60 50-59 < 50
Tumor Size ≤ 2 cm 2-3 cm > 3 cm
T Stage T1 Tis and T2 T3-T4
Nodal biopsy Yes - No
Margins Negative (≥ 2 mm) Close (< 2 mm) Positive
Histology Invasive ductal or other favorable subtypes Invasive Lobular -
Pure DCIS No ≤ 3c m >3c m
ER Receptor Positive Negative -
LVSI* No Limited/Focal Extensive
EIC* No ≤ 3c m >3c m
* Presence of LVSI and EIC were considered cautionary in this study. Multicentricity, multifocality, neoadjuvant chemo/endocrine therapy, and known BRCA1/2
mutations were not present in any patients in this study. Pathologic nodal stage was pN0 for all patients who underwent axillary assessment
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